PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY

Sedivet®

Boehringer Ingelheim

Injectable sedative for horses

Composition
1 mL aqueous solution for injection contains 10 mg Romifidine hydrochloride.

Action
The sedative effect of Sedivet® is induced by a stimulation of presynaptic alpha-2-receptors in the central nervous system. Sedivet® is an alpha-2-agonist with specific affinity for these receptors. Administration of Sedivet® results in dose-dependent sedation, with associated tolerance of pain.

Indications
Sedative to facilitate handling, examination and treatment, and as a premedication agent prior to general anaesthesia.
Sedation for:
- Transportation
- x-ray examination
- manipulations/interventions of the head and neck and procedures such as tooth care, bronchoscopy, laryngoscopy, irrigation of gultural pouches, etc.
- manipulations/interventions in the trunk and limb region, and for abscess lancing, minor surgery combined with a local anaesthesia, rectal and vaginal palpation
- supportive therapy for tetanus

Sedivet® can be used as a premedication agent prior to the induction of general anaesthesia. Induction of anaesthesia may be initiated 8–10 minutes after administration of Sedivet®.

DIRECTIONS FOR USE
DO NOT USE IN PREGNANT MARES
Injection to be given intravenously.
Lowering of the head is the first sign of sedation.
Light sedation:
0.04 mg active ingredient/kg bodyweight equals 0.4 mL injection solution/100 kg bodyweight
Deep sedation:
0.08 mg active ingredient/kg bodyweight equals 0.8 mL injection solution/100 kg bodyweight
Deep sedation with prolonged duration:
0.12 mg active ingredient/kg bodyweight equals 1.2 mL injection solution/100 kg bodyweight

As with other alpha-2-sympathomimetics, horses under sedation with Sedivet® may demonstrate increased skin sensitivity of the hindlimbs. The usual precautions while handling horses should always be observed, even when sedated.

For painful interventions, particularly in the hindlimb region, combined use of Sedivet® with morphine-like analgesics (such as butorphanol hydrate) is recommended.

Sedivet® has not been tested on pregnant mares.

The effect of Sedivet® may be potentiated by other psychoactive compounds, such as tranquillisers, other sedatives or morphine like analgesics.

Sedivet® induces side effects typical of alpha-2-sympathomimentics; bradycardia and hypotension. Occasionally Sedivet® induces second degree AV blocks. These effects can be avolved/reversed using atropine.

Do not use with TMPS containing products.

WITHHOLDING PERIOD
Do not administer later than 6 days before slaughter for human consumption.

First Aid
If poisoning occurs, contact a doctor or Poisons Information Centre.
Phone Australia 131116;
New Zealand 03 4747000.

Disposal
Dispose of empty container by wrapping with paper and putting in garbage.

Storage
Store below 30°C
(Room Temperature).

Presentation
20 mL multi-dose vials

Australia
Boehringer Ingelheim Pty Limited
Animal Health Division
Level 1
78 Waterloo Road
NORTH RYDE, N.S.W. 2113

NRA 35980/1100

New Zealand
Boehringer Ingelheim (NZ) Limited
Animal Health Division
Level 1, Unit 9
42 Ormiston Road
East Tamaki, Auckland

Restricted Veterinary Medicine. No. A6097
See www.nzfsa.govt.nz/acvm
for registration conditions.

43572/006